Details of the Drug

General Information of Drug (ID: DME2CAK)

• Drug Name: Myo-inositol hexaphosphate
• Synonyms: Phytic acid; 83-86-3; Phytate; Fytic acid; Inositol hexaphosphate; Alkalovert; myo-Inositol hexaphosphate; myo-inositol hexakisphosphate; Alkovert; Phytine; Acidum fyticum; Acide fytique; Acido fitico; myo-Inositol, hexakis(dihydrogen phosphate); myo-Inosistol hexakisphosphate; inositol hexakisphosphate; Inositol 1,2,3,4,5,6-hexakisphosphate; CCRIS 4513; UNII-7IGF0S7R8I; Saure des phytins [German]; Saeure des phytins; Acidum fyticum [INN-Latin]; Acido fitico [INN-Spanish]; Acide fytique [INN-French]; Inosithexaphosphorsaure; Phytate; SNF-03; SNF-04; SNF-471; SNF-472; SNF-571; SNF-671; Calcium metabolism modulator (transdermal patch formulation, cardiovascular calcifications), Sanifit Laboratoris SL; InsP6 (transdermal patch formulation, cardiovascular calcifications), Sanifit Laboratoris SL; Phytate (intravenous formulation, cardiovascular calcifications), Sanifit Laboratoris SL; Phytate (tablet formulation, osteoporosis), Sanifit Laboratoris SL; Phytate (transdermal patch formulation, cardiovascular calcifications), Sanifit Laboratoris SL; Calcium metabolism modulator (subcutaneous/injectable formulation, cardiovascular calcifications), Sanifit Laboratoris SL; Myo-inositol hexakisphosphate (transdermal patchformulation, cardiovascular calcifications), Sanifit Laboratoris SL; Myo-inositol hexaphosphate (intravenous formulation, cardiovascular calcifications), Sanifit Laboratoris SL; Myo-inositol hexaphosphate (tablet formulation, osteoporosis), Sanifit Laboratoris SL; Myo-inositol hexaphosphate (transdermal patch formulation, cardiovascular calcifications), Sanifit Laboratoris SL; Phytate (transdermal/patch formulation, renal calcium lithiasis), Sanifit Laboratoris SL; SNF-471 (transdermal patch, cardiovascular calcification), Sanifit; SNF-571 (transdermal patch, renal calcium lithiasis), Sanifit; InsP6, (transdermal/patch formulation, renal calcium lithiasis), Sanifit Laboratoris SL; Myo-inositol hexaphosphate (transdermal/patch formulation, renal calcium lithiasis), Sanfit Laboratoris SL; RP-3000

Indication

Disease Entry	ICD 11	Status	REF
Cardiovascular disease	BA00-BE2Z	Phase 2/3	[1]
Gastroesophageal reflux disease	DA22.Z	Investigative	[2]

• Drug Type: Small molecular drug
• Chemical Identifiers:
  Formula: C6H18O24P6
  Canonical SMILES: C1(C(C(C(C(C1OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O
  InChI: InChI=1S/C6H18O24P6/c7-31(8,9)25-1-2(26-32(10,11)12)4(28-34(16,17)18)6(30-36(22,23)24)5(29-35(19,20)21)3(1)27-33(13,14)15/h1-6H,(H2,7,8,9)(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)(H2,19,20,21)(H2,22,23,24)
  InChIKey: IMQLKJBTEOYOSI-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 890
  ChEBI ID: CHEMBL17401
  CAS Number: 83-86-3
  UNII: 7IGF0S7R8I
  DrugBank ID: DB14981
  TTD ID: D0KN1U
• Drug-Molecule Activity Atlas (DMA)NEW: Click to Jump to the Detailed DMA Information of This Drug
• Drug ADMET Endpoint Profile (DAE)NEW: Click to Jump to the Detailed DAE Information of This Drug
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

References

• [1] ClinicalTrials.gov (NCT01000233) Value of Oral Phytate (InsP6) in the Prevention of Progression of the Cardiovascular Calcifications. U.S. National Institutes of Health.
• [2] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.